| Patent application number | Description | Published |
|---|
| 20080260715 | Precursor N-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme - The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form. | 10-23-2008 |
| 20090191178 | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof - This invention provides compositions of highly phosphorylated lysosomal enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases. | 07-30-2009 |
| 20090269346 | Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for LRP2 and Uses Thereof - The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins. | 10-29-2009 |
| 20090281024 | Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof - The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. | 11-12-2009 |
| 20100028370 | MEGALIN-BASED DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUES - The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier. | 02-04-2010 |
| 20100210517 | CYCLIC RECEPTOR-ASSOCIATED PROTEIN (RAP) PEPTIDES - The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. | 08-19-2010 |
| 20100303797 | Use of p97 As An Enzyme Delivery System For The Delivery of Therapeutic Lysosomal Enzymes - The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier. | 12-02-2010 |
| 20110142763 | Megalin-Based Delivery of Therapeutic Compounds to the Brain and Other Tissues - The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier. | 06-16-2011 |
